[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B. Chin J Hepatol, 2005, 13: 881-891. (in Chinese)
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol, 2011, 19: 13-24. (in Chinese)
[3] Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol, 2011, 54: 6-8.
[4] Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol, 2008, 48 suppl 1: S2-19.
[5] Lee M, Keeffe EB. Hepatitis B: modern end points of treatment and the specter of viral resistance. Gastroenterol Clin North Am, 2011, 40:495-505.
[6] Farnik H, Lange CM, Hofmann WP, et al. Nucleos (t) ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. J Clin Virol, 2011, 52: 204-209.
[7] Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007, 357: 2576-2588.
[8] Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology, 2008, 47: 447-454.
[9] Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol, 2009, 51: 11-20.
[10] Yuen MF, Lai CL. Telbivudine for chronic hepatitis B: the GLOBE trial. Future Virol, 2008, 3: 317-323.
[11] Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther, 2009, 14: 13-22.
[12] Lampertico P, Vigano M, Manenti E, et al. Add-on adefovir prevents the emergence of adefovir resistance in lamivudine-resistant patients: A 4-year study. J Hepatol, 2008, 48: S259.
[13] Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007, 46: 1695-1703.
[14] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology, 2009, 136: 486-495.
[15] Yuen MF, Fung J, Seto WK, et al. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther, 2009, 14: 679-685.
[16] Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology, 2010, 52: 1611-1620.
[17] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol, 2008, 6:1315-1341.
[18] Almeida AM, da Silva AL, Cherchiglia ML, et al. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. Value Health, 2011, 14 (5 suppl 1): S24-28.
[19] Wiens A, Venson R, Correr CJ, et al. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis, 2011, 15: 225-230.
[20] Marignani M, Canzoni M, D'Amelio R, et al. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. Eur J Intern Med, 2011, 22: 576-581.
[21] Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology, 2011, 141: 1212-1219.
[22] Heathcote J, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate freatment for chronic hepatitis B. Gastroenterology, 2011, 140: 132-143.
[23] Chen Y, Li X, Ye B, et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antivir Res, 2011, 91:23-31.